Quiver Bioscience and QurAlis Announce Research Collaboration to Advance Novel Therapeutic Approach for Fragile X Syndrome
Quiver's GPS platform integrates unique-in-world, scalable, human neuronal electrophysiology data (the 'language' of the brain) with artificial intelligence and machine learning (AI/ML) to drive novel insights into disease biology and enable optimized drug discovery. Quiver has successfully applied its GPS approach to a variety of central nervous system (CNS) disorders and recently published modeling and drug discovery efforts in FXS.
'Our platform technology is uniquely suited to improving understanding of the molecular and cellular basis of neurogenetic disorders such as FXS. We are excited to embark on this partnership with QurAlis which aspires to bring about groundbreaking therapies for the FXS community,' said Graham Dempsey, Ph.D., co-founder and CEO of Quiver Bioscience.
'FXS is a devastating neurodevelopmental disease. It is the leading inherited form of intellectual disability and known cause of autism for which there are no disease-modifying therapies,' said Kasper Roet, Ph.D., CEO and co-founder of QurAlis. 'We look forward to this research collaboration with Quiver. The combination of enabling technologies and drug development experience built through this partnership holds great promise for progressing novel therapeutics for FXS, for which there exists a significant unmet medical need.'
FXS, the leading genetic form of intellectual disability and autism spectrum disorder, is caused by loss of the FMR1 encoded protein Fragile X Messenger Ribonucleoprotein (FMRP). It currently affects approximately 87,000 individuals in the U.S. alone – occurring at an incidence of 1 in 4,000 males and 1 in 6,000 females. In addition to intellectual disability, FXS symptoms include delays in development, seizures, speech difficulties, hyperactivity and attention deficit, severe anxiety, and others. There are no disease-modifying therapies currently available for FXS.
Destum Partners acted as transaction advisor to Quiver Bioscience.
About Quiver Bioscience
Quiver Bioscience is a technology-driven company established to create transformational medicines for the brain while simultaneously uncovering new biology and novel, effective drug targets. Using advanced single-cell imaging and multi-omics, we are building the world's most information-rich neuronal insight map via our "Genomic Positioning System." Our approach integrates cutting-edge scalable human models, state-of-the-art technology and proprietary engineering, and learning and surrogate AI/ML models to identify novel therapeutic targets and the best candidate molecules to deliver new and meaningful therapeutics to patients. For information, including additional publications describing application of Quiver's GPS to drug discovery, visit www.quiverbioscience.com or follow us on LinkedIn.
About QurAlis Corporation
At QurAlis, we are neuro pioneers on a quest to cure, boldly seeking to translate scientific breakthroughs into powerful precision medicines. We work collaboratively with a relentless pursuit of knowledge, precise attention to craft, and compassion to discover and develop medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases. QurAlis is the leader in development of precision therapies for amyotrophic lateral sclerosis (ALS). In addition to ALS, QurAlis is advancing a robust precision medicine pipeline to bring effective disease-modifying therapeutics to patients suffering from severe diseases defined by genetics and clinical biomarkers. For more information, please visit www.quralis.com or follow us on X @QurAlisCo or LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Trimble Stock Outlook: Is Wall Street Bullish or Bearish?
With a market cap of $19.7 billion, Trimble Inc. (TRMB) is a global technology company that provides advanced positioning, surveying, construction, and transportation management solutions. Leveraging GPS, GNSS, optical, laser, and wireless communications technologies, Trimble serves industries such as architecture, engineering, construction, logistics, and asset management worldwide. Shares of the Westminster, Colorado-based company have outperformed the broader market over the past 52 weeks. TRMB stock has surged 62.5% over this time frame, while the broader S&P 500 Index ($SPX) has rallied 20.1%. Moreover, shares of Trimble are up 18.5% on a YTD basis, compared to SPX's 8.6% rise. More News from Barchart Robinhood Stock Seemingly Can't Be Stopped in 2025. Is It Too Late to Buy HOOD Here? Dear Ford Stock Fans, Mark Your Calendar for August 11 Cathie Wood Is Buying Shares of This Little-Known Ethereum Treasury Company. Should You? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. In addition, shares of the navigation equipment maker have outpaced the Technology Select Sector SPDR Fund's (XLK) 29.6% return over the past 52 weeks. Shares of Trimble rose 1.7% on Aug. 6 after the company reported Q2 2025 adjusted EPS of $0.71 and revenue of $875.7 million, above the forecasts. The company raised its annual revenue guidance to $3.5 billion - $3.6 billion and lifted its adjusted EPS outlook to $2.90 - $3.06. Investor optimism was further fueled by strong demand for its integrated hardware and software solutions, successful bundling of prepackaged product suites, and growing use of AI tools in customer workflows. For the current fiscal year, ending in December 2025, analysts expect TRMB's EPS to grow 6.3% year-over-year to $2.35. The company's earnings surprise history is mixed. It beat the consensus estimates in three of the last four quarters while missing on another occasion. Among the 11 analysts covering the stock, the consensus rating is a 'Strong Buy.' That's based on eight 'Strong Buy' ratings, one 'Moderate Buy,' and two 'Holds.' On Aug. 7, Raymond James raised its price target on Trimble to $93, maintaining an 'Outperform' rating. As of writing, the stock is trading below the mean price target of $87.58. The Street-high price target of $95 implies a potential upside of 13.3% from the current price levels. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Medscape
2 days ago
- Medscape
Patient Input Shapes Family Planning Care in Psoriasis
TOPLINE: A cross-sectional survey of patients with psoriasis found that the majority expressed concerns regarding fertility, heredity, and the safety of psoriasis treatments during family planning or pregnancy and preferred to receive guidance from dermatologists or GPs at diagnosis or during medication changes. METHODOLOGY: Researchers conducted a cross-sectional questionnaire study including adult female and male patients with psoriasis, regardless of their treatment type. An online questionnaire was developed using the Castor Electronic Data Capture System in collaboration with specialists and patient representatives. Questions covered disease characteristics, treatment experiences in the period trying to conceive or during pregnancy, and experiences and preferences regarding information provision on family planning and pregnancy (FPP). Researchers analysed responses from 102 participants (69.6% women and 30.4% men). Among the female respondents, 33 had (biological) children, 37 had no children, and one was pregnant for the first time at the moment of questionnaire completion. TAKEAWAY: Patients identified dermatologists and GPs as their preferred sources for information about FPP. Of all respondents who obtained information about FPP, 7.9% reported having "complete access," 42.1% reported having "enough access," 42.1% reported having "moderate access," and 7.9% reported having "insufficient access" to information. Information needs focused on fertility, heredity of psoriasis, use of medication, and, specifically for females, disease course during and after pregnancy and breastfeeding. Patients with prior biologic therapy more often requested fertility information than those without (70.8% vs 40.6%; P = .026). Parents also more frequently sought guidance on fertility (79.3% vs 44.4%) and medication use during conception and/or pregnancy (72.4% vs 37.0%; P = .008 for both) than non-parents. Timing preferences for receiving information about FPP included the moment of diagnosis and medication changes or upon explicit request. Disease activity improved in 61.7% of completed pregnancies, and it increased in 46.7% of cases postpartum. IN PRACTICE: "In conclusion, the findings of this study have led to hands-on guidance for healthcare professionals to improve healthcare for both male and female patients with psoriasis in the reproductive age," the authors of the study wrote. SOURCE: This study was led by Liana Barenbrug, Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands. It was published online on July 30, 2025, in the Journal of Dermatological Treatment. LIMITATIONS: This study overrepresented biologic-treated patients and relied on self-reported data, which may be subject to recall bias. Additionally, none of the respondents used systemic medication during conception or pregnancy, limiting insights into this important subgroup of patients. DISCLOSURES: This study did not receive any funding. Some authors reported receiving research grants and speaking fees and having other ties with various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Business Wire
3 days ago
- Business Wire
NextNav Inc. Reports Second Quarter 2025 Results and Operational Highlights
RESTON, Va.--(BUSINESS WIRE)--NextNav Inc. (NASDAQ: NN) a leader in next generation positioning, navigation, and timing (PNT) and 3D geolocation, today reported its financial results and operational updates for the quarter ended June 30, 2025. ' In the second quarter we continued to advance toward our goal of addressing one of our nation's most critical infrastructure needs with a sense of urgency and purpose,' said Mariam Sorond, CEO of NextNav. ' We appreciate the FCC's order granting consent to the assignment of the Telesaurus licenses, further enhancing our spectrum position and operational leadership in the Lower 900MHz band. We substantiated with data and analysis the significant benefits and minimal costs of our proposal to optimize the Lower 900 MHz band. We look forward to continuing to support the FCC's important work as we seek to enable a widescale, future-proof complement and backup to GPS as quickly as possible.' Operational Highlights On May 13, 2025, NextNav filed reply comments in response to the FCC's Notice of Inquiry, Promoting the Development of PNT Technologies and Solutions, making the case for the FCC to promptly issue a Notice of Proposed Rulemaking that would enable a terrestrial complement and backup to GPS without the need for multibillion dollar taxpayer expenditures. The filing can be found here. On June 10, 2025, NextNav presented implementation and deployment details of our 5G-based PNT solution to FCC staff. Details can be found here. On June 20, 2025, the FCC issued an order granting consent to the assignment of 128 active M-LMS licenses to NextNav and waived an FCC rule that forbids one licensee from holding both an A-block license and a B- or C-block license in the same license area. The order can be found here. On June 24, 2025, NextNav's CEO participated in an event focused on the urgent need for GPS resiliency, featuring distinguished Congressional, FCC, DoD and public safety representatives. Details of the event can be found here. On July 9, 2025, NextNav filed a supplemental technical study further validating the assumptions and conclusions in our February 2025 technical study, demonstrating that introducing 5G operations will not cause unacceptable interference to unlicensed Part 15 devices in the Lower 900 MHz band. The filing can be found here. On July 17, 2025, NextNav submitted an economic report prepared by the Brattle Group establishing that NextNav's proposed optimization of the Lower 900 MHz band would impose minimal costs while generating substantial national benefits, potentially amounting to tens of billions of dollars. The filing can be found here. On August 1, 2025, NextNav filed a study with the FCC demonstrating that licensed tolling operations can coexist with 5G operations in the Lower 900 MHz band. The filing can be found here. Three and Six Months Ended June 30, 2025 Financial Highlights Revenue: was $1.2 million in the three months ended June 30, 2025, compared to $1.1 million in the prior year period. In the six months ended June 30, 2025, revenue was $2.7 million, compared to $2.2 million in the prior-year period. The increase in both three and six months ended June 30, 2025 was primarily driven by an increase in service revenue from technology and services contracts with government and commercial customers. Operating Loss: was $17.2 million in the three months ended June 30, 2025, compared to $15.3 in the prior year period, primarily driven by increases in professional services, payroll-related expenses, non-recurring engineering services, and outside consulting expenses, partially offset by lower software license and cloud expenses. In the six months ended June 30, 2025, operating loss was $34.2 million, as compared to $31.5 million in the prior year period, primarily driven by increases in professional services, outside consulting expenses, and non-recurring engineering services, partially offset by lower software license and cloud expenses. Net Loss: was $63.2 million in the three months ended June 30, 2025, including a loss on change in the fair value of derivative liability and warrants of $39.5 million, as compared to a net loss of $24.4 million in the prior year period, including a loss on the fair value of warrants of $8.5 million. In the six months ended June 30, 2025, net loss was $121.8 million, including a loss on the fair value of derivative liability and warrants of $58.0 million and debt extinguishment loss of $14.4 million as compared to a net loss of $56.0 million in the prior year period, including a loss on the fair value of warrants of $21.7 million. Balance Sheet: As of June 30, 2025, the Company had $58.9 million in cash and cash equivalents and $117.2 million in short-term investments. Net long-term debt of $246.3 million includes derivative liability of $93.8 million, and is net of unamortized discount of $37.5 million, with a face value of $190.0 million. Conference Call Information NextNav will host a conference call for analysts and investors at 5:00 pm ET on Wednesday, August 6, 2025. Registration for the conference call can be completed by visiting the following website prior to, or on the day of, the conference call: After registering, each participant will be provided with call details and a registrant ID. Reminders will also be sent to registered participants via email. Alternatively, the conference call will be available via a live webcast. To access the live webcast or a replay, visit the Company's investor relations website at To receive replay details, please register through the link above. After registering for replay details, each participant will be provided with call details and access codes to listen to the call playback. About NextNav Inc. NextNav Inc. (Nasdaq: NN) is a leader in next-generation 3D Positioning, Navigation, and Timing (PNT) solutions. As the nation's largest license holder in a spectrum band expressly designated for terrestrial positioning services, NextNav is uniquely positioned to enable a widescale terrestrial complement and backup to GPS. Leveraging licensed low-band spectrum and the global 5G ecosystem, NextNav is focused on delivering an accurate, reliable, and resilient 3D PNT solution to protect national security, public safety, and the economy. Learn more at For more information, please visit or follow NextNav on Twitter or LinkedIn. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as 'forecast,' 'intend,' 'seek,' 'target,' 'anticipate,' 'believe,' 'expect,' 'estimate,' 'plan,' 'outlook,' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements, which involve risks and uncertainties, relate to analyses and other information that are based on forecasts of future results and estimates of amounts not yet determinable and may also relate to NextNav's future prospects, developments and business strategies. In particular, such forward-looking statements include the achievement of certain FCC-related milestones and FCC approvals, the ability to realize the broader spectrum capacity and the advancement of NextNav's terrestrial 3D PNT services, NextNav's position to drive growth in its 3D geolocation business and expansion of its next generation terrestrial 3D PNT technologies, the business plans, objectives, expectations and intentions of NextNav, and NextNav's estimated and future business strategies, competitive position, industry environment, potential growth opportunities, revenue, expenses, and profitability. These statements are based on NextNav's management's current expectations and beliefs, as well as a number of assumptions concerning future events. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside NextNav's control that could cause actual results to differ materially from the results discussed in the forward-looking statements. These risks, uncertainties, assumptions and other important factors include, but are not limited to, those included in Part II, Item 1A, 'Risk Factors' of the Company's quarterly reports on Form 10-Q, and Part I, Item 1A, 'Risk Factors' of the NextNav's Annual Report on Form 10-K for the year ended December 31, 2024, as well as those otherwise described or updated from time to time in our other filings with the Securities and Exchange Commission (the 'SEC'). You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and NextNav undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. (unaudited) December 31, 2024 Assets Current assets: Cash and cash equivalents $ 58,866 $ 39,330 Short term investments 117,186 40,785 Accounts receivable 2,237 3,301 Other current assets 3,663 2,629 Total current assets $ 181,952 $ 86,045 Property and equipment, net of accumulated depreciation of $15,742 and $13,716 at June 30, 2025 and December 31, 2024, respectively 15,981 17,974 Operating lease right-of-use assets 16,417 17,368 Goodwill 19,094 16,966 Intangible assets 9,637 9,589 Other assets 13,662 13,798 Total assets $ 256,743 $ 161,740 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,610 $ 858 Accrued expenses and other current liabilities 7,369 8,536 Operating lease current liabilities 2,824 2,462 Deferred revenue 353 288 Total current liabilities $ 12,156 $ 12,144 Warrants 30,261 28,707 Operating lease noncurrent liabilities 13,483 14,352 Other long-term liabilities 1,763 1,795 Long term debt, net 246,295 54,621 Total liabilities $ 303,958 $ 111,619 Stockholders' equity: Common stock, authorized 500,000,000 shares; 133,146,901 and 131,268,940 shares issued and 133,014,673 and 131,136,712 shares outstanding at June 30, 2025 and December 31, 2024, respectively 15 14 Additional paid-in capital 933,537 912,241 Accumulated other comprehensive income 3,806 665 Accumulated deficit (983,880 ) (862,106 ) Common stock in treasury, at cost; 132,228 shares at both June 30, 2025 and December 31, 2024 (693 ) (693 ) Total stockholders' equity (deficit) $ (47,215 ) $ 50,121 Total liabilities and stockholders' equity $ 256,743 $ 161,740 Expand NEXTNAV INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenue $ 1,202 $ 1,105 $ 2,741 $ 2,151 Operating expenses: Cost of goods sold (exclusive of depreciation and amortization) 2,035 2,924 4,568 5,685 Research and development 4,824 4,110 8,862 8,780 Selling, general and administrative 10,233 8,108 20,753 16,554 Depreciation and amortization 1,350 1,295 2,802 2,613 Total operating expenses $ 18,442 $ 16,437 $ 36,985 $ 33,632 Operating loss $ (17,240 ) $ (15,332 ) $ (34,244 ) $ (31,481 ) Other income (expense): Interest expense, net (3,020 ) (2,320 ) (5,758 ) (4,489 ) Debt extinguishment loss — — (14,434 ) — Change in fair value of warrants (8,836 ) (8,490 ) (2,795 ) (21,666 ) Change in fair value of derivative liability (30,658 ) — (55,181 ) — Other income (loss), net (3,399 ) 1,820 (9,262 ) 1,748 Loss before income taxes $ (63,153 ) $ (24,322 ) $ (121,674 ) $ (55,888 ) Provision for income taxes (42 ) (68 ) (100 ) (112 ) Net loss $ (63,195 ) $ (24,390 ) $ (121,774 ) $ (56,000 ) Foreign currency translation adjustment 2,149 (179 ) 3,141 (701 ) Comprehensive loss $ (61,046 ) $ (24,569 ) $ (118,633 ) $ (56,701 ) Net loss (63,195 ) (24,390 ) (121,774 ) (56,000 ) Net loss attributable to common stockholders $ (63,195 ) $ (24,390 ) $ (121,774 ) $ (56,000 ) Weighted average of shares outstanding – basic and diluted 132,318 115,210 131,509 119,359 Net loss attributable to common stockholders per share - basic and diluted $ (0.48 ) $ (0.21 ) $ (0.93 ) $ (0.47 ) Expand NEXTNAV INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (IN THOUSANDS) Six Months Ended June 30, 2025 2024 Operating activities Net loss $ (121,774 ) $ (56,000 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 2,802 2,613 Equity-based compensation 7,974 7,896 Change in fair value of warrants 2,795 21,666 Debt extinguishment loss 13,734 — Issuance of common warrants 9,006 — Change in fair value of derivative liability 55,181 — Change in fair value of asset purchase agreement liability — (1,878 ) Realized and unrealized gain on short term investments (1,160 ) (254 ) Equity method investment loss 74 81 Asset retirement obligation accretion 52 32 Amortization of debt discount 4,275 2,950 Changes in operating assets and liabilities: Accounts receivable 1,064 84 Other current assets (918 ) 24 Other assets 67 (53 ) Accounts payable 752 754 Deferred revenue 65 (82 ) Accrued expenses and other liabilities (120 ) 2,365 Operating lease right-of-use assets and liabilities 428 523 Net cash used in operating activities $ (25,703 ) $ (19,279 ) Investing activities Purchases of network assets, property, and equipment (57 ) (181 ) Purchase of internal use software (200 ) (262 ) Purchase of marketable securities (132,141 ) (26,144 ) Sale and maturity of marketable securities 56,900 7,000 Payment for asset purchase agreement liability — (2,732 ) Net cash used in investing activities $ (75,498 ) $ (22,319 ) Financing activities Proceeds from 2028 senior convertible notes 190,000 — Repayment of 2026 senior secured notes (70,000 ) — Payments towards debt issuance cost (1,517 ) — Payments towards debt (56 ) (55 ) Proceeds from exercise of common warrants 582 21,036 Redemption of non-controlling interests — 40 Proceeds from exercise of common stock options 1,422 1,650 Net cash provided by financing activities $ 120,431 $ 22,671 Effect of exchange rates on cash and cash equivalents 306 22 Net increase (decrease) in cash and cash equivalents 19,536 (18,905 ) Cash and cash equivalents at beginning of period 39,330 81,878 Cash and cash equivalents at end of period $ 58,866 $ 62,973 Capital expenditure included in Accrued expenses and other current liabilities $ 22 $ 156 Interest paid in shares of common stock $ — $ 1,867 Interest paid in cash $ 4,244 $ 1,750 Expand
